A Phase IV Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma That is Not Responding to Four or More Standard Treatments or Has Come Back After Several Standard Treatments

This is a Phase 4, multicenter, open-label, single-arm study evaluating the safety and efficacy of elranatamab monotherapy in adult participants with relapsed or refractory multiple myeloma in India. Eligible participants must have received at least four prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody. All enrolled participants will receive elranatamab; there is no comparator or control arm. Approximately 100 participants are planned to be enrolled across approximately 10 study sites in India. Study assessments will include evaluation of disease response and monitoring of adverse events in accordance with the study protocol.